Skip to content

Top 10 Pharma Stocks in India for September 2026

Sector Alpha's September 2026 ranking of pharma stocks worth ₹2,000 crore or more, from the weekly scan to 1 October 2026, put Acutaas Chemicals (78/100), Neuland Laboratories (77/100) and Kwality Pharmaceuticals (76/100) at the top. The score weighs growth, business quality, valuation against history and price strength. Source: Sector Alpha weekly scan.

  1. 1Acutaas Chemicals78scoreGrowthQualityValuationPriceGrowth 91 · Quality 80 · Valuation 52 · Price strength 79
  2. 2Neuland Laboratories77scoreGrowthQualityValuationPriceGrowth 96 · Quality 80 · Valuation 67 · Price strength 51
  3. 3Kwality Pharmaceuticals76scoreGrowthQualityValuationPriceGrowth 91 · Quality 64 · Valuation 56 · Price strength 84
  4. 4Shukra Pharmaceuticals75scoreGrowthQualityValuationPriceGrowth 87 · Quality 77 · Valuation 46 · Price strength 81
  5. 5IOL Chemicals & Pharmaceuticals74scoreGrowthQualityValuationPriceGrowth 82 · Quality 50 · Valuation 67 · Price strength 95
  6. 6Glenmark Pharmaceuticals72scoreGrowthQualityValuationPriceGrowth 88 · Quality 73 · Valuation 63 · Price strength 53
  7. 7Laurus Labs71scoreGrowthQualityValuationPriceGrowth 92 · Quality 73 · Valuation 26 · Price strength 76
  8. 8Senores Pharmaceuticals70scoreGrowthQualityValuationPriceGrowth 93 · Quality 68 · Valuation 49 · Price strength 52
  9. 9Gland Pharma69scoreGrowthQualityValuationPriceGrowth 75 · Quality 56 · Valuation 67 · Price strength 75
  10. 10Ipca Laboratories67scoreGrowthQualityValuationPriceGrowth 75 · Quality 63 · Valuation 55 · Price strength 68

Not frozen yet: this September 2026 ranking is worked out again from the stored weekly scores each time the page is built, so it follows today's rule. Once a month is frozen, it never changes.

See the latest pharma stocks ranking and full list.

← Previous monthNext month →

Disclosure: Sector Alpha is not a SEBI-registered research analyst. This page is information and education only, not a recommendation to buy, sell or hold any security. No price targets are given. Data: NSE prices through our weekly pipeline. Past performance does not indicate future results.

More lists

All 20 lists, grouped